Chemotherapy in chronic organic brain syndrome--a review of the literature.
D000925:Anticoagulants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001927:Brain Diseases / Q000188:drug therapy*; D002090:Butyrophenones / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D004876:Ergot Alkaloids / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D010208:Papaverine / Q000627:therapeutic use; D010640:Phenothiazines / Q000627:therapeutic use; D008517:Phytotherapy; D010946:Plants, Medicinal; D011926:Rauwolfia / Q000627:therapeutic use; D013892:Thioxanthenes / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000925:Anticoagulants; D000928:Antidepressive Agents; D002090:Butyrophenones; D000697:Central Nervous System Stimulants; D004876:Ergot Alkaloids; D006993:Hypnotics and Sedatives; D010640:Phenothiazines; D013892:Thioxanthenes; D014665:Vasodilator Agents; D010208:Papaverine